News
Accelerating Innovation and Full Integration | CP Pharmaceutical and Sino Biopharm Hold 2022 CEO Conference
Release time：2022-10-27
Recently, CP Pharmaceutical Group and Sino Biopharm held the 2022 CEO Conference, where representatives from Group headquarters, Chia tai Tianqing, Beijing Tide, Nanjing Chia tai Tianqing, Chia tai Qingdao, Chia tai Fenghai, Chia tai Qingjiang, invoX and other subsidiaries gathered to stimulate thinking and share wisdom.
Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm, delivered a keynote speech on "Focusing on Global Innovation, Accelerating Global Layout, and Promoting High Quality Development". Miss Tse, Theresa Y Y pointed out that we must persistently adhere to innovation-driven development, focus on the Group's four strategic directions and four advantageous therapeutic areas, take the Chinese market as our foundation, and steadily move towards the international pharmaceutical market. At the same time, we must adhere to green and low-carbon development, actively introduce innovative technologies and attract global research talents; accelerate the layout of innovative drugs to provide safer and more effective treatment solutions for patients.
Miss Tse, Theresa Y Y said that in the past three years, the Group has launched a total of 61 new drugs, providing strong growth momentum. Especially in the NASH field, where there is a huge market gap, we have actively laid out oral and injectable products to meet different clinical needs. At the beginning of this year, we introduced two biologics from Anyuan Bio, FGF21 and FGF21/GLP1 fusion protein, which are currently the first in China in terms of progress in the same target. Last month, we also completed the introduction of the world's first FDA-approved Phase III oral PPAR agonist with Inventiva in France. With this transaction, the Group has achieved full coverage of important small and large molecule targets in the field of NASH, forming a leading and competitive pipeline layout in China with mutual synergy and iterative upgrade.
With the goal of achieving $100 billion in revenue by 2030, Miss Tse, Theresa Y Y emphasized that the company will implement a "two-wheeled parallel" strategy to accelerate the deployment of the next "Anlotinib" innovative drug through internal R&D. On the other hand, the BD team will be asked to accelerate the introduction of heavyweight products that fill clinical gaps and complement the company's pipeline.
Mr. Tse, Eric S Y, Chief Executive Officer of Sino Biopharm and Chairman of CTTQ Pharmaceutical Group, gave a keynote speech on "Efficient Operation, Innovation and Commercialization Leading Development", interpreting the key words of the 20th Party Congress Report related to medicine and health, and analyzing Sino Biopharm's four strategies, corporate culture and four areas of "organizational integration, comprehensive innovation, internationalization and digitalization".
He pointed out that the report of the 20th National Congress proposed to "promote the construction of a healthy China and put the protection of people's health in a strategic position of priority development", which pointed out the direction for the development of China's health, and enterprises should pay sufficient attention to it and implement it. Mr. Tse, Eric S Y said that the changes in policy, industry and social environment require companies to unify their understanding, firstly, to target the innovative drug track, "self-development + BD + clinical" troika-driven development; secondly, to have more efficient commercialization capabilities, the group level to maximize the integration of commercialization resources; thirdly, to improve operational efficiency, the group needs to integrate organizations.
During the conference, experts from J.P Morgan, Huatai Securities and Boston Consulting Group shared their insights on the development trend of biopharmaceutical industry from various dimensions, such as policy environment, international trends, capital trends and innovation ecology.
During the conference, representatives of the participating companies were divided into five groups to discuss how to accelerate the integration and synergy, sharing and co-creation of the five major sectors: R&D, internal, external, production and procurement. The participants also held group discussions on external cooperation to bring in and go out.
